Patent Claim Denied on Rheumatoid Arthritis Biosimilar

Article

A patent for a rheumatoid arthritis drug was ruled invalid, but Johnson & Johnson plans to appeal the decision.

Johnson & Johnson (J&J) is the latest pharmaceutical manufacturer to use patent-infringement lawsuits to delay the entrance of biosimilars into the market.

Infliximab (Remicade) costs approximately $1300 to $2500 per dose, and can treat symptoms related to rheumatoid arthritis, and other inflammatory conditions. The biosimilar version of the drug was created by Hospira Healthcare Corp, which is owned by Pfizer and Celltrion Healthcare Co.

Cellitron is currently marketing the biosimilar in Europe and Canada. The company said in a press release that the drug has been driving the company’s revenue growth. A judge recently ruled that the biosimilar does not infringe on any patents Johnson & Johnson has for Remicade.

The District of Massachusetts Federal Court stated that the company’s patent (US Patent No. 6,284,471) for Remicade is invalid, thus also invalidating the lawsuit. However, the company plans to file an appeal relating to the patent.

J&J said in a press release that they plan to defend their intellectual property rights.

“A commercial launch of an infliximab biosimilar prior to the outcome of the appeals would be considered an at-risk launch,” the company wrote.

It is clear that J&J will follow the tactics of other manufacturers to prevent a cheaper biosimilar version of their top earning drug, which brought in $6.6 billion worldwide last year, from launching.

Recent Videos
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
BIOSIMILARS - pharmaceutical concept | Image Credit: hafakot - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Portrait of young female pharmacist holding medication while using computer at pharmacy counter | Image Credit: Dragana Gordic - stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background. Science and Medical concept. Scientist research and analysis biotechnology concept - Image credit: Shutter2U | stock.adobe.com
Health care professional holding adalimumab
lexiconimages - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.